Fulcrum Therapeutics, Inc. Operating Income Loss

• Fulcrum Therapeutics, Inc. showed a decrease of -287.1% in Operating Income Loss from 2024 to 2025.
• This data is from Fulcrum Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 24, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Fulcrum Therapeutics, Inc.'s Operating Income Loss has declined by 153.1%.
• Historical annual values: Fiscal year 2025: -$84.77 million | Fiscal year 2024: -$21.90 million | Fiscal year 2023: -$110.66 million | Fiscal year 2022: -$112.56 million | Fiscal year 2021: -$81.05 million | Fiscal year 2020: -$71.61 million | Fiscal year 2019: -$84.22 million | Fiscal year 2018: -$33.50 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026